"Enzyme Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.
| Descriptor ID |
D004791
|
| MeSH Number(s) |
D27.505.519.389
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Enzyme Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Enzyme Inhibitors".
This graph shows the total number of publications written about "Enzyme Inhibitors" by people in this website by year, and whether "Enzyme Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 1995 | 12 | 10 | 22 |
| 1996 | 11 | 18 | 29 |
| 1997 | 11 | 23 | 34 |
| 1998 | 12 | 21 | 33 |
| 1999 | 16 | 29 | 45 |
| 2000 | 20 | 32 | 52 |
| 2001 | 25 | 47 | 72 |
| 2002 | 27 | 49 | 76 |
| 2003 | 46 | 72 | 118 |
| 2004 | 28 | 55 | 83 |
| 2005 | 24 | 51 | 75 |
| 2006 | 26 | 42 | 68 |
| 2007 | 34 | 44 | 78 |
| 2008 | 14 | 44 | 58 |
| 2009 | 18 | 31 | 49 |
| 2010 | 15 | 16 | 31 |
| 2011 | 23 | 11 | 34 |
| 2012 | 12 | 26 | 38 |
| 2013 | 11 | 10 | 21 |
| 2014 | 14 | 13 | 27 |
| 2015 | 17 | 11 | 28 |
| 2016 | 18 | 9 | 27 |
| 2017 | 17 | 11 | 28 |
| 2018 | 12 | 14 | 26 |
| 2019 | 10 | 9 | 19 |
| 2020 | 15 | 9 | 24 |
| 2021 | 12 | 10 | 22 |
| 2022 | 2 | 10 | 12 |
| 2023 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Enzyme Inhibitors" by people in Profiles.
-
Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations. Blood Cancer J. 2023 02 17; 13(1):27.
-
Evaluation of an EZH2 inhibitor in patient-derived orthotopic xenograft models of pediatric brain tumors alone and in combination with chemo- and radiation therapies. Lab Invest. 2022 02; 102(2):185-193.
-
Therapeutic Response in Pediatric Neuromyelitis Optica Spectrum Disorder. Neurology. 2023 02 28; 100(9):e985-e994.
-
IMPDH inhibition activates TLR-VCAM1 pathway and suppresses the development of MLL-fusion leukemia. EMBO Mol Med. 2023 01 11; 15(1):e15631.
-
AL101, a gamma-secretase inhibitor, has potent antitumor activity against adenoid cystic carcinoma with activated NOTCH signaling. Cell Death Dis. 2022 08 05; 13(8):678.
-
Targeting NAAA counters dopamine neuron loss and symptom progression in mouse models of parkinsonism. Pharmacol Res. 2022 08; 182:106338.
-
Turning Nonselective Inhibitors of Type I Protein Arginine Methyltransferases into Potent and Selective Inhibitors of Protein Arginine Methyltransferase 4 through a Deconstruction-Reconstruction and Fragment-Growing Approach. J Med Chem. 2022 09 08; 65(17):11574-11606.
-
Structure-activity relationship and antitumor activity of 1,4-pyrazine-containing inhibitors of histone acetyltransferases P300/CBP. Eur J Med Chem. 2022 Jul 05; 237:114407.
-
Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial. Clin Cancer Res. 2022 04 14; 28(8):1540-1548.
-
A phase 1 study of IDH305 in patients with IDH1R132-mutant acute myeloid leukemia or myelodysplastic syndrome. J Cancer Res Clin Oncol. 2023 Mar; 149(3):1145-1158.